Ann: Change of Director's Interest Notice - Chris Ntoumenopoulos, page-106

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 106 Last

Share
Profile

Follow
Myeverywish

3,464 Posts.

956

24/03/21

12:35

Post #: 52001648
Share

Originally posted by DickyB ↑

I'm positive about Ilara as well. I spoke with TK about a month ago and he said the trial was going very well.

He did go on to say that he doesn't expect to make millions from an Ilara Health agreement but for me it's about the product being useful in the real world and I'm sure there will be some decent income over time. DX is absolutely perfect for this setting and a big reason the Gates foundation funded the Professor at the outset was that pneumonia is a big problem over there, especially in kids. We absolutely have the potential to make a game changing difference in the early detection of respiratory illness in these places that have no xray or other medical equipment that we take for granted.

If it works well it gives us massive validation with all our potential telehealth partners and we'll certainly get seriously noticed by some important organisations if it proves to be a success.

I'm very tempted to pick up the phone and ask TK about the progress with the Medgate trial but I'll be patient and give it a few more weeks. Again DX is perfect for Medgate and Medgate perfect for DX.

I'm remaining grounded but if we can diagnose Covid 19 with reasonable accuracy the application potential is mind blowing. Telehealth, DTC, airport screening, etc. New cases are still on the increase worldwide.

There must be a lot going on at Resapp HQ at the minute. By June 30 we could have the following:

Signed Medgate deal
FDA SleepCheck
Ilara Health validation and deal
Progress with DX FDA approval
A few left field deals

Oh and the ability to accurately detect Covid 19 with a smartphone.

IMO GLTAH!

Expand

Yes...
Very Happy

MB

RAP Price at posting: 7.1¢ Sentiment: Buy Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 1 more message in this thread...

First 106 Last

Add RAP (ASX) to my watchlist

Ann: Change of Director's Interest Notice - Chris Ntoumenopoulos, page-106

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News